- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00812539
Diabetes Connect: Patients and Providers Use of a Secure Website for Blood Glucose Monitoring in Type-2 Diabetes
A Randomized Clinical Trial of a Secure Website Shared Between Patients and Providers for Blood Glucose Monitoring in Type-2 Diabetes
Study Overview
Status
Conditions
Detailed Description
The study will be carried out at multiple practices within Partners HealthCare system and will have one Intervention and one control arm.
Subjects enrolled into the intervention arm will use a OneTouch Ultra2 glucometer and an iMetrikus modem device which will upload the blood glucose readings to a secure, login-enabled web-based portal. Subjects will be given login information to access to their own individual Internet site, where they can view their readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their patients' information on the web portal).
Subjects enrolled into the control arm will have access to the same glucometer and modem, and will have access to another individual internet website (the "Basic Site") which will show their glucose readings and graphical representation of glucose levels. Each patient will be enrolled for 3 months. and the primary outcome measure will patient and provider satisfaction with the Diabetes Connected Health tool.The specific aims along with hypothesis of the study are:
To develop a web-based application ("Diabetes Connected Health") that will enable home-based glucose monitoring results to be readily incorporated into clinical glycemic management.
Hypothesis: We hypothesize that through a development process incorporating interactive feedback loops between software developers, patients, clinicians, and other stakeholders, we can create a web-based clinical application that will be adopted by clinical practices.
- To test the impact of the "Diabetes Connected Health" tool in a randomized clinical trial.
Hypothesis: We hypothesize that implementation of the tool will have a beneficial impact relative to control patients in several critical domains:
Patient Domains
- Increase patients' knowledge of their diabetes management plan.
- Increase patients' satisfaction with their clinical care.
- Increase patients' awareness of why they have high and/or low glucose readings.
- Increase patients' satisfaction with patient-provider communication.
Provider Domains
- Increase clinician satisfaction with clinical care.
- Increase clinician knowledge of individual patient care issues.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Partners HealthCare Hospitals/Clinics (Massachusetts General Hospital, Brigham and Womens Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligibility Criteria for Partners HealthCare practices:
Manage type-2 Diabetes patients.
Have at least one non-Physician provider (nurse practitioner, nurse, diabetes educator) with responsibility for diabetes patient care
Inclusion Criteria for subject selection:
Diagnosis of type 2 diabetes
Age 18 years or older
English speaking/able to read English
Last measured Hemoglobin A1c (HbA1c) > 7.5 % in the last 12 months.
Prescribed glucose self-monitoring, and either currently self monitoring or willing to monitor their blood glucose, as prescribed by their care provider, using the OneTouch Ultra2 portable glucometer.
Access to the Internet for the 6 months the study will run.
Access to a compatible analog telephone line at either their work place or home such that the subjects are able to upload the glucometer readings to the website.
Access to an active email account.
Receiving diabetes care primarily within the practice.
Exclusion Criteria for subject selection:
Subjects having mental health, cognitive or physical impairments that would preclude the set up and use of the modem, glucometer or computer.
Subjects are not candidates for guideline-based diabetes care.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diabetes Connected Health Tool "Deluxe"
Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer.
An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal.
Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
|
Subjects enrolled into the "Deluxe"intervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal ("Diabetes Connected Health" tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system).
Subjects with new high or low readings will be flagged.
Providers can initiate messages to subjects regarding symptoms or medications.
A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading.
|
|
Active Comparator: Diabetes Connected Health Tool "Basic"
Control group will measure their glucose levels by using a glucometer.
An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal.
Participants will be given login information to access this portal.
where they can view their glucose readings in tabular form.
Their physicians will not have access to this information.
|
Patients enrolled in the Diabetes Connect "Basic" intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the "Diabetes Connected Health" tool) where they can view their readings in a less detailed/journal fashion.
No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management.
Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subject and provider satisfaction with the intervention.
Time Frame: Upon completion of the trial.
|
Upon completion of the trial.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subject knowledge of diabetes and motivation
Time Frame: On completion of the trial
|
On completion of the trial
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard W. Grant, MD, MPH, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008-P-001898/1; MGH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria